Biomerica Company Profile (OTCMKTS:BMRA)

About Biomerica (OTCMKTS:BMRA)

Biomerica logoBiomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians' offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company's diagnostic products use immunoassay technology.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:BMRA
  • CUSIP: N/A
  • Web:
  • Market Cap: $24 million
  • Outstanding Shares: 8,511,000
Average Prices:
  • 50 Day Moving Avg: $2.70
  • 200 Day Moving Avg: $2.51
  • 52 Week Range: $1.53 - $3.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.59
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.79 million
  • Price / Sales: 4.15
  • Book Value: $0.53 per share
  • Price / Book: 5.32
  • EBIDTA: ($735,414.00)
  • Net Margins: -23.86%
  • Return on Equity: -29.80%
  • Return on Assets: -26.43%
  • Average Volume: 12,644 shs.
  • Beta: 0.27
  • Short Ratio: 0.17

Frequently Asked Questions for Biomerica (OTCMKTS:BMRA)

What is Biomerica's stock symbol?

Biomerica trades on the OTCMKTS under the ticker symbol "BMRA."

How were Biomerica's earnings last quarter?

Biomerica, Inc. (OTCMKTS:BMRA) released its earnings results on Tuesday, January, 17th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.17 million. Biomerica had a negative return on equity of 29.80% and a negative net margin of 23.86%. View Biomerica's Earnings History.

Who are some of Biomerica's key competitors?

Who are Biomerica's key executives?

Biomerica's management team includes the folowing people:

  • Zackary S. Irani, Chairman of the Board, Chief Executive Officer
  • Francis E. Capitanio, President
  • Janet Moore, Chief Financial Officer, Treasurer, Secretary, Director
  • Allen C. Barbieri, Independent Director
  • Francis R. Cano Ph.D., Independent Director
  • Jane F. Emerson M.D. Ph.D., Independent Director
  • Mark A. Sirgo, Independent Director

How do I buy Biomerica stock?

Shares of Biomerica can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biomerica's stock price today?

One share of Biomerica stock can currently be purchased for approximately $2.82.

MarketBeat Community Rating for Biomerica (OTCMKTS BMRA)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biomerica (OTCMKTS:BMRA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Biomerica (OTCMKTS:BMRA)
No equities research coverage for this company has been tracked by


Earnings History for Biomerica (OTCMKTS:BMRA)
Earnings by Quarter for Biomerica (OTCMKTS:BMRA)
Earnings History by Quarter for Biomerica (OTCMKTS BMRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/17/2017Q2 2017($0.03)($0.02)$1.17 million$1.43 millionViewN/AView Earnings Details
10/15/2015Q1 2016($0.02)($0.01)$1.32 million$1.29 millionViewN/AView Earnings Details
4/15/2015Q3 2015($0.01)($0.02)$1.50 million$1.30 millionViewN/AView Earnings Details
1/15/2015Q2 2015($0.01)($0.03)$1.40 million$1.13 millionViewN/AView Earnings Details
10/16/2014Q1 2015($0.03)($0.03)$1.24 million$1.03 millionViewN/AView Earnings Details
9/2/2014Q4 2014$0.02$0.02$1.43 million$1.68 millionViewN/AView Earnings Details
1/15/2014Nov 2013($0.01)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biomerica (OTCMKTS:BMRA)
Current Year EPS Consensus Estimate: $-0.09 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS


Dividend History for Biomerica (OTCMKTS:BMRA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biomerica (OTCMKTS:BMRA)
Insider Trades by Quarter for Biomerica (OTCMKTS:BMRA)
Insider Trades by Quarter for Biomerica (OTCMKTS:BMRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/27/2017Francis E CapitanioPresidentSell15,000$2.46$36,900.00View SEC Filing  
1/4/2017Janet MooreCFOSell4,500$2.20$9,900.00View SEC Filing  
12/22/2016Janet MooreCFOSell9,780$2.18$21,320.40View SEC Filing  
12/12/2016Francis E CapitanioPresidentSell9,351$2.77$25,902.27View SEC Filing  
12/8/2016Francis E CapitanioPresidentSell10,649$2.89$30,775.61View SEC Filing  
11/14/2016Zackary S IraniCEOBuy400$1.94$776.00View SEC Filing  
11/8/2016Zackary S IraniCEOBuy500$1.74$870.00View SEC Filing  
11/4/2016Zackary S IraniCEOBuy1,000$1.95$1,950.00View SEC Filing  
10/20/2016Francis E CapitanioPresidentSell10,000$2.68$26,800.00View SEC Filing  
10/3/2016Jane EmersonDirectorBuy1,000$2.80$2,800.00View SEC Filing  
9/7/2016Zackary S IraniCEOBuy199$2.65$527.35View SEC Filing  
8/12/2016Janet MooreCFOBuy2,200$2.98$6,556.00View SEC Filing  
8/12/2016Zackary S IraniInsiderBuy3,166$2.98$9,434.68View SEC Filing  
8/11/2016Zackary S IraniCEOBuy3,700$2.88$10,656.00View SEC Filing  
8/10/2016Zackary S IraniCEOBuy1,000$2.72$2,720.00View SEC Filing  
8/9/2016Allen BarbieriDirectorBuy3,000$2.54$7,620.00View SEC Filing  
8/5/2016Francis CanoDirectorBuy16,300$2.37$38,631.00View SEC Filing  
8/3/2016Mark A SirgoDirectorBuy4,000$2.05$8,200.00View SEC Filing  
8/3/2016Zackary S IraniCEOBuy2,609$2.10$5,478.90View SEC Filing  
8/2/2016Mark A SirgoDirectorBuy8,000$1.97$15,760.00View SEC Filing  
8/1/2016Zackary S IraniCEOBuy5,400$1.88$10,152.00View SEC Filing  
5/16/2016Francis E CapitanioPresidentSell20,000$1.50$30,000.00View SEC Filing  
11/13/2015Zackary S IraniCEOBuy5,000$0.83$4,150.00View SEC Filing  
6/8/2015Zackary S IraniCEOBuy3,000$1.08$3,240.00View SEC Filing  
5/22/2015Zackary S IraniCEOBuy2,000$0.85$1,700.00View SEC Filing  
5/11/2015Zackary S IraniCEOBuy18,000$0.91$16,380.00View SEC Filing  
9/6/2012Zackary S IraniCEOBuy7,000$0.70$4,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biomerica (OTCMKTS:BMRA)
Latest Headlines for Biomerica (OTCMKTS:BMRA)
DateHeadline logoAnalyst Sees >35% Upside in Shares of Biomerica, Inc. - September 20 at 5:24 PM logoBiomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test - September 12 at 5:02 PM logoBMRA Looking To Capitalize On Strong OUS Growth With Expanded Distribution - September 6 at 4:37 PM logoBiomerica, Inc. :BMRA-US: Earnings Analysis: Q4, 2017 By the Numbers : August 31, 2017 - August 31 at 4:30 PM logoBiomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for the year - August 30 at 5:55 PM logoBiomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for the year - August 30 at 5:55 PM logoBiomerica, Inc. :BMRA-US: Earnings Analysis: 2017 By the Numbers : August 30, 2017 - August 30 at 5:55 PM logoBiomerica, Inc. :BMRA-US: Earnings Analysis: 2017 By the Numbers : August 30, 2017 - August 30 at 5:55 PM logoBiomerica, Inc. (BMRA) Scheduled to Post Earnings on Monday - August 21 at 2:08 AM logoBioamerica inks distribution deal in Mexico; shares ahead 2% - August 17 at 11:08 PM logoBiomerica, Inc. (BMRA) Reports Point of Care Product Distribution Agreement with Multi-National Pharmaceutical Company - August 17 at 11:08 PM logoBiomerica Announces Point of Care Product Distribution Agreement with a Multinational Pharmaceutical Company - August 16 at 5:09 PM logoBiomerica to present at the 18th Annual B. Riley & Co. investor conference on May 24, 2017 - May 23 at 12:02 PM logoBMRA: Base Business Bouncing Back With Three Quarters of Sequential Growth - April 18 at 3:53 PM logoBiomerica, Inc. :BMRA-US: Earnings Analysis: Q3, 2017 By the Numbers : April 18, 2017 - April 18 at 12:45 PM logoBiomerica Announces Third Quarter Financial Results, Sales up 13.9% for Nine Months - April 17 at 12:27 PM logoBiomerica to present at the 29th Annual ROTH conference on March 13, 2017 - March 9 at 4:33 PM logoBMRA: Analysis of IBS Drugs Indicates Unmet Need for Alternative Therapies - January 26 at 4:39 PM logoBiomerica Announces Second Quarter Financial Results; Sales up Over 22% for the Quarter - January 18 at 3:23 PM logoBIOMERICA INC Files SEC form 10-Q, Quarterly Report - January 17 at 4:43 PM logoBiomerica to Present at the 9th Annual LD Micro Main Event - November 30 at 10:33 AM logoBIOMERICA INC Financials - October 21 at 3:53 PM logoBMRA: Base Business Bounces Back, InFoods Continues To Attract Who’s-Who of IBS - October 20 at 3:24 PM logoBiomerica Announces First Quarter Fiscal 2017 Financial Results, Sales Increase Over Prior Year - October 18 at 8:44 AM logoBiomerica Highlights Recent Scientific Reports Indicating Increased Prevalence of IBS - October 4 at 8:39 AM logoBMRA: Progress of InFoods Prompts Upward Revision to Valuation - September 6 at 3:37 PM logoProgress of InFoods Prompts Upward Revision to Valuation - September 6 at 3:37 PM logoExclusive: Newly-Listed Biomerica's CEO Talks IBS, Tech And Patient Care - September 6 at 2:55 PM logoBiomerica to Present at 18th Annual Rodman & Renshaw Global Investment Conference - September 6 at 8:44 AM logoHEB Gets Some Relief, ITEK Awaits Data In Dec., NYMX Abuzz, FDA Snubs AMGN - August 25 at 8:46 AM logoBiomerica, Inc. (BMRA) Cleared to List on Nasdaq CM - August 24 at 3:52 PM logo8:20 am Biomerica common stock has been approved for listing on the Nasdaq Capital Market, expects to commence trading on Aug 26 - August 24 at 12:08 PM logoBiomerica Updates Shareholders on Progress of Commercialization of Its New IBS Product - August 10 at 3:20 PM logoBMRA: More Positive Clarity on InFoods' FDA Pathway - July 13 at 10:20 AM logoFDA Determines That Biomerica's Proposed InFoods(R) IBS Clinical Investigation Is a Nonsignificant Risk (NSR) Device Study - July 11 at 7:47 AM logoBiomerica Signs Exclusive License Agreement for Korean Market With Total Value of up to $8.5 Million; Licensee Makes Equity Investment of $1m in Biomerica at $3 per Share - May 26 at 9:09 AM logoBIOMERICA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities - May 26 at 8:49 AM logoBiomerica Announces Third Quarter Financial Results, Sales up 10% for Nine Months - April 15 at 7:47 AM logoAll Board Members of Biomerica to Purchase Biomerica Common Stock Shares in the Open Market - April 7 at 8:19 AM logoBIOMERICA INC Files SEC form 8-K, Other Events - March 16 at 6:07 AM logoBiomerica Announced That Its International Patent Application for IBS Was Reviewed by the ISA and All Claims Have Been Deemed Novel and Non-Obvious - March 14 at 8:19 AM logoBiomerica to Present at the ROTH Conference on March 16, 2016 - March 10 at 8:49 AM logoBMRA: Q2 Results, IBS Advisory Board Beefed Up Further - January 19 at 12:00 PM logoBiomerica Announces Second Quarter Financial Results - January 15 at 8:19 AM



Biomerica (BMRA) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff